Q2 2026 Adjusted EBITDA exceeded expectations at $1.304 billion, with strong growth in both ambulatory and hospital segments. FY 2026 guidance was raised for Adjusted EBITDA and free cash flow, supported by robust cash flow, significant deleveraging, and active capital deployment.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.